News

Business Wire5mon
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP) - Business Wire
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP) - āshibio advances lead program into safety and ...
Science Daily1y
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva - ScienceDaily
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine , 2023; DOI: 10.1038/s41591-023-02561-8 Cite This Page : ...
Business Wire1y
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis - Business Wire
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis. November 13, 2023 07:00 AM Eastern Standard Time.